In a report published Friday, Canaccord Genuity reiterated its Buy rating on Amarin Corporation (NASDAQ: AMRN), but lowered its price target from $26.00 to $19.00 .
Canaccord Genuity noted, “Reiterate BUY, lowering target to $19 ; maintain positive view on Vascepa commercial, partnering potential while acknowledging increased commercial risk. We continue to expect business development talks to intensify and Vascepa to receive NCE (five-year exclusivity). Our $19 target is based on a sum-of-the-parts analysis, combining a DCF of high triglyceride sales and pNPV of mixed dyslipidemia sales.”
Amarin Corporation closed on Thursday at $11.95 .